Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Ontada®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, has announced a strategic collaboration with Datavant, a health data ...

Janney Montgomery Scott LLC lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 0.3% in the third quarter, according ...

New Delhi: The drug major Sanofi has got approval from the Subject Expert Committee ... She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

PeopleImages / Getty Images The term “tax break” refers to a benefit offered by the government that reduces your total tax liability. Tax breaks are made possible by tax laws and typically ...

boonchai wedmakawand / Getty Images Bilateral tax agreements between countries help prevent double taxation for individuals and businesses. A bilateral tax agreement, a type of tax treaty signed ...

Do I always have to pay tax on my income? Tax-free allowances reduce the amount of tax you have to pay on income you receive. There are two types: Allowances – allow you to earn a certain amount of ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Genome & Co. Ltd. has reported preclinical findings of its anti-CNTN4 antibody, GENA-104A16, and anti-APP antibody, 5A7 — stressing the contactin-4 (CNTN4) and amyloid precursor protein (APP) axis as ...

Sanofi and the nuclear corporation Orano have agreed to coinvest in a new Orano subsidiary that will develop radioligands based on lead-212 α-emitting isotopes. Sanofi will invest about $325 ...

Sanofi has begun 2013 on a positive note after announcing that it has 65 New Molecular Entity (NME) projects and vaccine candidates in clinical development. Of this 65, 17 are already in phase 3 ...